Form 4: SELLAS Life Sciences Grants 300,000 RSUs to CDO

SELLAS Life Sciences Group, Inc. awarded 300,000 restricted stock units to SVP, Chief Development Officer Dragan Cicic, vesting over several years.

Summary

• Dragan Cicic, SVP, Chief Development Officer of SELLAS Life Sciences Group, Inc. (SLS), received an award of 300,000 restricted stock units (RSUs).
• The transaction date for this equity award was January 7, 2026.
• The RSUs will vest in tranches: 25% on December 1, 2026, and 25% on each subsequent December 1 until fully vested.
• Vesting is contingent upon Dragan Cicic remaining in service with the Issuer through each respective vesting date.
• Following this transaction, Dragan Cicic beneficially owns 557,805 shares of common stock directly.
• The acquisition price for these restricted stock units was $0.00, as it represents an award.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive signal for executive retention and alignment of interests with shareholders, reflecting a standard compensation practice.

Positives

• The grant of 300,000 restricted stock units to a key executive, Dragan Cicic, aligns his interests with long-term shareholder value.
• The multi-year vesting schedule acts as a retention incentive for a Senior Vice President and Chief Development Officer, encouraging continued commitment to the company's success.

Negatives

• The restricted stock units do not provide immediate liquidity or cash value to the reporting person until they vest and are settled.
• The ultimate value of the award is dependent on the future stock price performance of SELLAS Life Sciences Group, Inc., introducing market risk.

Risks

• The value of the restricted stock units is subject to the market price fluctuations of SELLAS Life Sciences Group, Inc.'s common stock.
• Vesting of the RSUs is conditional on the reporting person's continued employment with the company through each vesting date, posing a risk of forfeiture if employment ceases.

Future Outlook

The vesting schedule for the restricted stock units extends through December 1, 2029, indicating a long-term commitment from the company to retain Dragan Cicic and align his incentives with future company performance and value creation.

Industry Context

Equity awards, such as restricted stock units, are a common component of executive compensation packages in the biotechnology and pharmaceutical industries. They are used to attract, retain, and motivate key talent by linking their personal wealth to the long-term success and stock performance of the company. This practice is particularly prevalent in growth-oriented sectors like life sciences where long development cycles require sustained executive commitment.

Comparison to Industry Standards

• The grant of restricted stock units to a Chief Development Officer is a standard practice for executive compensation in the biotech sector, comparable to similar awards seen at companies like Moderna, BioNTech, or Gilead Sciences for their senior R&D or development executives.
• The multi-year vesting schedule (25% annually over four years) is also a common structure designed to ensure long-term retention and alignment of executive interests with shareholder value, consistent with industry benchmarks for executive equity incentives.

Stakeholder Impact

• Shareholders: The award aligns the interests of a key executive with long-term shareholder value, potentially leading to better decision-making focused on stock performance.
• Employees: This type of award can serve as a benchmark for other employees, indicating the company's approach to executive compensation and retention.

Next Steps

• The first tranche of 25% of the restricted stock units will vest on December 1, 2026.
• Subsequent tranches of 25% will vest on December 1 of each year thereafter until fully vested, contingent on continued service.

Key Dates

Keywords

SELLAS Life Sciences Group, SLS, Restricted Stock Units, RSU, Equity Award, Insider Transaction, Executive Compensation, Dragan Cicic, Form 4